Inclusion Criteria:  Must be a pathologically proven Hepatocellular Carcinoma Must have been treated with regorafenib Regorafenib must be used after two lines of standard antitumor therapy  Exclusion Criteria:  Application is less than one course of treatment with regorafenib First - or second-line treatment with regorafenib Patients with multiple primary cancers